Journal of Neuroimmunology
Volume 218, Issue 1 , Pages 1-2 , 25 January 2010

Sphingosine-1-phosphate and its receptors as a possible therapeutic target in autoimmune diseases of the nervous system

Received 19 September 2009 ,Revised 24 September 2009 ,Accepted 25 September 2009.

References 

  1. Archelos JJ, Mäurer M, Jung S, Miyasaka M, Tamatani T, Toyka KV, et al. Inhibition of experimental autoimmune neuritis by an antibody to the lymphocyte function-associated antigen-1. Lab. Invest. 1994;70:667–675
  2. Archelos JJ, Previtali SC, Hartung HP. The role of integrins in immune-mediated diseases of the nervous system. Trends Neurosci. 1999;22:30–38
  3. Cyster JG. Lymphoid organ development and cell migration. Immunol. Rev. 2003;195:5–14
  4. Enders U, Lobb R, Pepinsky RB, Hartung HP, Toyka KV, Gold R. The role of the very late antigen-4 and its counterligand vascular cell adhesion molecule-1 in the pathogenesis of experimental autoimmune neuritis of the Lewis rat. Brain. 1998;121:1257–1266
  5. Gold R, Stoll G, Kieseier BC, Hartung HP, Toyka KV. Experimental autoimmune neuritis. In:  Dyck PJ,  Thomas PK editor. Peripheral Neuropathy. Vol. 2:Elsevier Saunders; 2005;p. 609–633
  6. Hughes JE, Srinivasan S, Lynch KR, Proia RL, Ferdek P, Hedrick CC. Sphingosine-1-phosphate induces an antiinflammatory phenotype in macrophages. Circ. Res. 2008;102:950–958
  7. Kataoka H, Sugahara K, Shimano K, Teshima K, Koyama M, Fukunari A, et al. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell. Mol. Immunol. 2005;2:439–448
  8. Kieseier BC, Kiefer R, Gold R, Hemmer B, Willison HJ, Hartung HP. Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve. 2004;30:131–156
  9. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu. Rev. Immunol. 2009;27:485–517
  10. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2000;47:707–717
  11. Miron VE, Jung CG, Kim HJ, Kennedy TE, Soliven B, Antel JP. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann. Neurol. 2008;63:61–71
  12. O'Connor P, Comi G, Montalban X, Antel J, Radue EW, de Vera A, et al. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology. 2009;72:73–79
  13. Pan S, Mi Y, Pally C, Beerli C, Chen A, Guerini D, et al. A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model. Chem. Biol. 2006;13:1227–1234
  14. Rivera J, Proia RL, Olivera A. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat. Rev. Immunol. 2008;8:753–763
  15. Schwab SR, Cyster JG. Finding a way out: lymphocyte egress from lymphoid organs. Nat. Immunol. 2007;8:1295–1301
  16. Waksman BH, Adams RD. Allergic neuritis: an experimental disease of rabbits induced by the injection of peripheral nervous tissue and adjuvants. J. Exp. Med. 1955;102:213–236
  17. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature. 1992;356:63–66
  18. Zhang Z, Zhang ZY, Fauser U, Schluesener HJ. FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves. Exp. Neurol. 2008;210:681–690
  19. Zhang, Z.Y., Zhang, Z., Zug, C., Nuesslein-Hildesheim, B., Leppert, D., Schluesener, H.J., 2009. AUY954, a selective S1P1 modulator, prevents experimental autoimmune neuritis. J. Neuroimmunol. doi:10.1016/j.jneuroim.2009.09.010.

PII: S0165-5728(09)00386-5

doi: 10.1016/j.jneuroim.2009.09.018

Journal of Neuroimmunology
Volume 218, Issue 1 , Pages 1-2 , 25 January 2010

Article Tools